Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
ConclusionsOsimertinib has a better effectiveness compared to all other TKIs. However, at a Dutch threshold of €80,000/QALY, osimertinib appears not to be cost-effective.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Cancer | Cancer & Oncology | Economics | Health Management | Lung Cancer | Netherlands Health | Non-Small Cell Lung Cancer | Study | Tarceva